Intas Pharmaceuticals Ltd — Carboplatin Exporter Profile
Indian Pharmaceutical Exporter · #12 for Carboplatin · $950.0K export value · DGFT Verified
Intas Pharmaceuticals Ltd is the #12 Indian exporter of Carboplatin with $950.0K in export value and 19 verified shipments. Intas Pharmaceuticals Ltd holds a 1.3% market share in Carboplatin exports across 6 countries.
Intas Pharmaceuticals Ltd — Carboplatin Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Ltd Export Carboplatin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| MEXICO | $1.7M | 37 | 48.8% |
| UNITED KINGDOM | $409.8K | 19 | 12.0% |
| CANADA | $352.7K | 11 | 10.3% |
| SOUTH AFRICA | $294.0K | 9 | 8.6% |
| PERU | $193.7K | 8 | 5.7% |
| ITALY | $115.2K | 8 | 3.4% |
| POLAND | $108.3K | 19 | 3.2% |
| NETHERLANDS | $75.7K | 14 | 2.2% |
| PHILIPPINES | $58.4K | 6 | 1.7% |
| MALAYSIA | $50.0K | 1 | 1.5% |
Intas Pharmaceuticals Ltd exports Carboplatin to 20 countries. The largest destination is MEXICO accounting for 48.8% of Intas Pharmaceuticals Ltd's Carboplatin shipments, followed by UNITED KINGDOM (12.0%) and CANADA (10.3%). These destinations reflect Intas Pharmaceuticals Ltd's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Carboplatin from Intas Pharmaceuticals Ltd?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ACCORD FARMA S A DE C V | MEXICO | $579.8K | 14 |
| TO THE ORDER | MEXICO | $392.9K | 17 |
| ACCORD FARMA S.A. DE C.V. | MEXICO | $349.1K | 7 |
| TO THE ORDER . | MEXICO | $200.0K | 4 |
| XXCORXXHEAXXHCAXX LTXX | MALTA | $179.6K | 10 |
| ACCORD HEALTHCARE LIMITED | MALTA | $179.4K | 9 |
| ACCORD HEALTHCARE C/O QESTMED (PTY) | SOUTH AFRICA | $159.2K | 5 |
| ACCORD HEALTHCARE INC | CANADA | $155.7K | 4 |
| ACCORD FARMA S.A.DE C.V | MEXICO | $150.0K | 3 |
| ACCORD HEALTHCARE C/O QESTMED | SOUTH AFRICA | $134.8K | 4 |
Intas Pharmaceuticals Ltd supplies Carboplatin to 51 buyers globally. The largest buyer is ACCORD FARMA S A DE C V (MEXICO), followed by TO THE ORDER (MEXICO) and ACCORD FARMA S.A. DE C.V. (MEXICO). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Carboplatin Export Value and How Much Does Intas Pharmaceuticals Ltd Contribute?
India exported $50.8M worth of Carboplatin through 3,637 shipments from 273 suppliers to 138 countries, serving 829 buyers globally. Intas Pharmaceuticals Ltd contributes $950.0K to this total, accounting for 1.3% of India's Carboplatin exports. Intas Pharmaceuticals Ltd ships Carboplatin to 20 countries through 51 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Ltd's Carboplatin Exports?
Intas Pharmaceuticals Ltd's average Carboplatin shipment value is $50.0K per consignment, based on 19 shipments totaling $950.0K. The largest destination is MEXICO (48.8% of Intas Pharmaceuticals Ltd's Carboplatin exports).
How Does Intas Pharmaceuticals Ltd Compare to Other Indian Carboplatin Exporters?
Intas Pharmaceuticals Ltd ranks #12 among 273 Indian Carboplatin exporters with a 1.3% market share. The top 3 exporters are FRESENIUS KABI ONCOLOGY LIMITED ($27.5M), INTAS PHARMACEUTICALS LIMITED ($4.9M), EUGIA PHARMA SPECIALITIES LIMITED ($3.3M). Intas Pharmaceuticals Ltd processed 19 shipments to 6 destination countries.
What Carboplatin Formulations Does Intas Pharmaceuticals Ltd Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMA DRUGS AND MEDI NUVAPLAST 150MG/15ML(1X1V) (E1) CARBOPLATIN INJECTION BP 10MG/ML(15 ML) AS PER INV | $250.0K | 5 |
| PHAR.DRUGS AND MED: NUVAPLAST 150MG/15ML(1X1V) (E1) CARBOPLATIN INJECTION BP 10MG/ML (15 ML) EACH ML CONTAINS: CARBOPLA | $200.0K | 4 |
| CARBOPLATIN INJECTION BP 600MG/60ML | $150.0K | 3 |
| PHARMA DRUGS & MEDI ACCORD-CARBOPLATIN 4 | $148.8K | 4 |
| PHARMACEUTICAL DRUGS AND MEDICINE : NUVAPLAST 450MG/45ML1X1V E1 EACH ML CONTAINS: CARBOPLATIN PH. EUR.. ##### 10 MG | $100.0K | 2 |
| PHARMACEUTICAL DRUGS AND MEDICINE : NUVAPLAST 450MG/45ML1X1V E1 EACH ML CONTAINS: CARBOPLATIN PH. EUR.. ##### 10 M | $100.0K | 2 |
| PHARMA DRUGS AND MEDI NUVAPLAST 450MG/45ML1X1V E1 EACH ML CONTAINS:CARBOPLATIN PH. EUR.10 MG WATER FOR INJECTIONS PH | $100.0K | 2 |
| PH.DRU.& MED. NUVAPLAST 450MG/45ML(1X1V) (E1) EACH ML CONTAINS: CARBOPLATIN PH.EUR 10 MG WATER FOR INJECTIONS | $100.0K | 2 |
| PHARMA DRUGS AND MEDI NUVAPLAST 450MG/45ML1X1V E1 EACH ML CONTAINS: CARBOPLATIN PH. EUR. 10 MG WATER FOR INJECTIONS | $71.1K | 2 |
| PHARM DRUG &MED:CARBOCORD-450CONE.FOR SOL.FOR.INFUSION EACH ML CONTAINS: CARBOPLATIN PH.EUR 10 MG WATER FOR INJECTIONS | $67.9K | 2 |
Intas Pharmaceuticals Ltd exports 139 distinct Carboplatin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMA DRUGS AND MEDI NUVAPLAST 150MG/15ML(1X1V) (E1) CARBOP with 5 shipments worth $250.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Carboplatin to Key Markets
What Intas Pharmaceuticals Ltd must comply with to export Carboplatin to its top destination countries
Mexico — COFEPRIS
Approval Process
Generic registration under Mexican health law. NOM standards apply.
Timeline: 12–18 months
GMP & Export Requirements
Mexican GMP (NOM-059-SSA1); COFEPRIS overseas inspection or PIC/S certificate
Sanitary Import Permit from COFEPRIS; import licence via SAT
Note: COFEPRIS participates in PIC/S, easing recognition of PIC/S certificates from Indian authorities.
United Kingdom — MHRA
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Ltd Compare to Nearest Carboplatin Exporters?
Exporters ranked immediately above and below #12 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 11 | PLEASANT EXPORTS | $1.1M | 24 | 1 | $44.7K |
| 9 | ACCURE LABS PRIVATE LIMITED | $950.0K | 19 | 1 | $50.0K |
| 12 | INTAS PHARMACEUTICALS LTD ★ | $950.0K | 19 | 6 | $50.0K |
| 13 | TEYRO LABS PRIVATE LIMITED | $934.6K | 27 | 1 | $34.6K |
| 14 | CELON LABORATORIES PRIVATE LIMITED | $628.5K | 45 | 11 | $14.0K |
Intas Pharmaceuticals Ltd ranks #12 among 273 Indian Carboplatin exporters. Average shipment value of $50.0K compared to the market average of $186.1K. The closest competitors by value are PLEASANT EXPORTS and ACCURE LABS PRIVATE LIMITED.
Which Indian Ports Ship Carboplatin Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 648 | 17.8% |
| SAHAR AIR | 519 | 14.3% |
| SAHAR AIR CARGO ACC (INBOM4) | 502 | 13.8% |
| DELHI AIR | 463 | 12.7% |
| HYDERABAD AIR | 126 | 3.5% |
| Bombay Air | 119 | 3.3% |
| Delhi Air | 104 | 2.9% |
| HYDERABAD ACC (INHYD4) | 99 | 2.7% |
Market Intelligence
Latest developments and market context
Detailed market intelligence for Carboplatin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Carboplatin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Ltd matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 209 individual customs records matching Intas Pharmaceuticals Ltd exporting Carboplatin, covering 139 formulations to 20 countries via 51 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 138+ countries, 829+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Carboplatin Export Data from Intas Pharmaceuticals Ltd
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Ltd's Carboplatin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Ltd
Company Profile
0 products · $0 total trade · 0 categories
Carboplatin Stats
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Ltd.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Carboplatin. For current shipment-level data, contact TransData Nexus.